Severe scalp ulcerations and granulomata during treatment with amivantamab
This case series of 9 patients with NSCLC is the first to detail the presentation and treatment of ulcerative scalp lesions associated with amivantamab, a bispecific antibody which targets both epithelial growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). At our instit...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621923000571 |
| _version_ | 1827313704355495936 |
|---|---|
| author | Jingjia J Zhou Lanyi N Chen Thomas Lehan Benjamin Herzberg Brian S Henick Michael Pitman Stephanie Gallitano Catherine A Shu |
| author_facet | Jingjia J Zhou Lanyi N Chen Thomas Lehan Benjamin Herzberg Brian S Henick Michael Pitman Stephanie Gallitano Catherine A Shu |
| author_sort | Jingjia J Zhou |
| collection | DOAJ |
| description | This case series of 9 patients with NSCLC is the first to detail the presentation and treatment of ulcerative scalp lesions associated with amivantamab, a bispecific antibody which targets both epithelial growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). At our institution, 33 % of all patients on amivantamab develop scalp ulcerations, following a classic presentation of papulopustular eruption of the face and trunk (9/9), paronychia (9/9), and oral mucositis (7/9). The scalp lesions began as follicular pustules, progressing to vegetative ulcerative plaques within 23 weeks. Ulcerations were refractory to treatment despite trials of multiple systemic therapies, including prednisone, acitretin, cyclosporine, secukinumab, and oral antibiotics. Prednisone offered the most substantial benefit while topical wound care including dressings and washes such as ketoconazole proprionate, sodium sulfacetamide & sulfur soap, salicylic acid shampoo, and Coloplast®/Duoderm®/Aquacel® dressings provided symptomatic relief. One patient also developed granulomas on her vocal cords. More research on treatment and prevention is needed, as 6/9 patients stopped amivantamab due to their skin toxicities. Meanwhile, oncologists and dermatologists must collaborate to monitor toxicities, prepare patients for the possibility of scalp ulcerations, and provide symptomatic relief whenever possible. |
| first_indexed | 2024-03-08T14:20:42Z |
| format | Article |
| id | doaj.art-fb40ea8364194d088cac38266c7b287f |
| institution | Directory Open Access Journal |
| issn | 2666-6219 |
| language | English |
| last_indexed | 2024-04-24T22:19:46Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Problems in Cancer: Case Reports |
| spelling | doaj.art-fb40ea8364194d088cac38266c7b287f2024-03-20T06:11:26ZengElsevierCurrent Problems in Cancer: Case Reports2666-62192024-03-0113100273Severe scalp ulcerations and granulomata during treatment with amivantamabJingjia J Zhou0Lanyi N Chen1Thomas Lehan2Benjamin Herzberg3Brian S Henick4Michael Pitman5Stephanie Gallitano6Catherine A Shu7Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USADivision of Hematology & Oncology, Columbia University Irving Medical Center, New York, NY, USADivision of Hematology & Oncology, Columbia University Irving Medical Center, New York, NY, USADivision of Hematology & Oncology, Columbia University Irving Medical Center, New York, NY, USADivision of Hematology & Oncology, Columbia University Irving Medical Center, New York, NY, USADepartment of Otolaryngology-Head and Neck Surgery, Columbia University Irving Medical Center, New York, NY, USADepartment of Dermatology, Columbia University Irving Medical Center, New York, NY, USADivision of Hematology & Oncology, Columbia University Irving Medical Center, New York, NY, USA; Corresponding author at: 161 Fort Washington Avenue, 3rd Floor, New York, NY 10032, USA.This case series of 9 patients with NSCLC is the first to detail the presentation and treatment of ulcerative scalp lesions associated with amivantamab, a bispecific antibody which targets both epithelial growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). At our institution, 33 % of all patients on amivantamab develop scalp ulcerations, following a classic presentation of papulopustular eruption of the face and trunk (9/9), paronychia (9/9), and oral mucositis (7/9). The scalp lesions began as follicular pustules, progressing to vegetative ulcerative plaques within 23 weeks. Ulcerations were refractory to treatment despite trials of multiple systemic therapies, including prednisone, acitretin, cyclosporine, secukinumab, and oral antibiotics. Prednisone offered the most substantial benefit while topical wound care including dressings and washes such as ketoconazole proprionate, sodium sulfacetamide & sulfur soap, salicylic acid shampoo, and Coloplast®/Duoderm®/Aquacel® dressings provided symptomatic relief. One patient also developed granulomas on her vocal cords. More research on treatment and prevention is needed, as 6/9 patients stopped amivantamab due to their skin toxicities. Meanwhile, oncologists and dermatologists must collaborate to monitor toxicities, prepare patients for the possibility of scalp ulcerations, and provide symptomatic relief whenever possible.http://www.sciencedirect.com/science/article/pii/S2666621923000571AmivantamabLazertinibScalpUlcerCase report |
| spellingShingle | Jingjia J Zhou Lanyi N Chen Thomas Lehan Benjamin Herzberg Brian S Henick Michael Pitman Stephanie Gallitano Catherine A Shu Severe scalp ulcerations and granulomata during treatment with amivantamab Current Problems in Cancer: Case Reports Amivantamab Lazertinib Scalp Ulcer Case report |
| title | Severe scalp ulcerations and granulomata during treatment with amivantamab |
| title_full | Severe scalp ulcerations and granulomata during treatment with amivantamab |
| title_fullStr | Severe scalp ulcerations and granulomata during treatment with amivantamab |
| title_full_unstemmed | Severe scalp ulcerations and granulomata during treatment with amivantamab |
| title_short | Severe scalp ulcerations and granulomata during treatment with amivantamab |
| title_sort | severe scalp ulcerations and granulomata during treatment with amivantamab |
| topic | Amivantamab Lazertinib Scalp Ulcer Case report |
| url | http://www.sciencedirect.com/science/article/pii/S2666621923000571 |
| work_keys_str_mv | AT jingjiajzhou severescalpulcerationsandgranulomataduringtreatmentwithamivantamab AT lanyinchen severescalpulcerationsandgranulomataduringtreatmentwithamivantamab AT thomaslehan severescalpulcerationsandgranulomataduringtreatmentwithamivantamab AT benjaminherzberg severescalpulcerationsandgranulomataduringtreatmentwithamivantamab AT brianshenick severescalpulcerationsandgranulomataduringtreatmentwithamivantamab AT michaelpitman severescalpulcerationsandgranulomataduringtreatmentwithamivantamab AT stephaniegallitano severescalpulcerationsandgranulomataduringtreatmentwithamivantamab AT catherineashu severescalpulcerationsandgranulomataduringtreatmentwithamivantamab |